World's First Triple-Target T-Cell Engager Therapy for Refractory Rheumatoid Arthritis
Professor Mu Rong's rheumatology and immunology team performed the world's first CD2-CD3-CD19 triple-target T-cell engager therapy for a patient with refractory RA. This marks the shift of RA treatment from inflammation blockade toward precise immune repair.
Peking University Third Hospital